Materials and Methods:
General Methods: B16 F10, H1975, A549 and PC3 cells were acquired from ATCC and subcultured according to manufacturer's recommendations. Taxol (paclitaxel) and doxorubicin were purchased from Sigma Aldrich and solubilized with DMSO for in vitro studies. Nsuccinimidyl-DFO was obtained from Macrocyclics (Dallas, TX) and used without further purification. Zirconium-89 was purchased from 3D Imaging, LLC (Maumelle, AR). Iodine-125 was purchased from Perkin Elmer.
Antibody generation and characterization: The protocols for biopanning, phage amplification, ELISA screening, IgG expression and purification, as well as affinity/specificity characterization of the isolated antibody clone C4, closely followed a previous publication 13 and the details will be published elsewhere. To characterize cell surface binding, suspension HEK6E cells were transfected with either human or mouse PD-L1 gene cloned in a CMV promoter-driven plasmid (Sino Biological, Beijing) . 48 hours later the cells were exposed to various concentration of C4 followed by a PE-labeled anti-human Fc-specific secondary antibody (Biolegend, San Diego). Mock transfection of cells using the same plasmid lacking PD-L1 gene was used as a negative control. Binding of C4 to the cells was quantified by the geometric mean fluorescence intensity (MFI) and the half maximal effective concentration (EC 50 ) was determined by the sigmoidal nonlinear regression equation.
Kinetic constants for C4 antibody against human and mouse PD-L1 (R&D and Sino Biological Inc.) were determined using an Octet RED384 instrument (ForteBio). Six concentrations of each antigen (250 nM, 125 nM, 62.5 nM, 31.25 nM, 15.625 nM and 7.812 nM for human PD-L1 and 4 µM, 2 µM, 1 µM, 500 nM, 250 nM and 125 nM for mouse PD-L1) were tested for binding to the C4 antibody immobilized on Anti-Human IgG Fc Capture biosensors (Fortebio). All measurements were performed at room temperature in 384-well microplates and the running buffer was PBS with 0.5% (w/v) bovine serum albumin (BSA) and 0.05% (v/v) Tween 20.
C4 antibody was loaded for 180 sec from a solution of 300 nM, baseline was equilibrated for 60 s, and then the antigens were associated for 600 s followed by 1200 sec disassociation. Between each sample, the biosensor surfaces were regenerated three times by exposing them to 10 mM glycine, pH 1.5 for 5 sec followed by PBS for 5 sec. Data were analyzed using a 1:1 interaction model on the ForteBio data analysis software 8.2.
Bioconjugation chemistry: C4 (208 µL at a concentration of 9.6 mg/mL) was dispersed in 200 µL of 0.1 M sodium bicarbonate buffer (pH 9.0). The final reaction mixture was adjusted to a total volume of 0.5 mL by adding a sufficient amount of 0.1 M sodium bicarbonate buffer. pIsothiocyanatobenzyl-desferrioxamine (Df-Bz-NCS) was dissolved in DMSO at a concentration of 20 mM. Df-Bz-NCS solution was added to the antibody solution to give a 3.9 molar excess of the chelator over the molar amount of mAb. The Df-Bz-NCS was added dropwise and mixed rigorously during the addition. The concentration of DMSO was kept below 2% v/v to avoid any precipitation. After 30 min at 37 o C, the reaction mixture was purified with a PD-10 column using a gentisic acid mobile phase (5 mg/mL of gentisic acid in 0.25 M sodium acetate, pH 5.4-5.6). The pH of the eluted C4-DFO solution was adjusted to 7.0 and stored at -20 o C until time of use.
Determination of relative binding affinity of DFO-C4: The binding of fixed concentration of a radioligand 125 I-C4 (0.4 µM) was also measured at equilibrium on PC3 and B16F10 cells in the presence of an incrementally increasing series of concentrations of a DFO-C4 and naked C4 (a range of 10µM to 1 pM). The cocktail was incubated at room temperature for 1 hour. Following incubation, the cells were washed twice with ice cold PBS and retained for analysis (unbound fraction). The cells were lysed with 1 mL of 1M NaOH and collected (cell associated fraction). The unbound and cell associated fractions were counted in a gamma counter and expressed as a percentage of the total activity added per number of cells. The data were plotted and the IC 50 was determined using PRISM software.
Radiochemistry: A solution of 89 Zr-oxalic acid (5mCi; 10 µl) was neutralized with 2 M Na 2 CO 3 (5 µl). After 3 min, 0.30 ml of 0.5 M HEPES (pH 7.1-7.3) and 0.5 mg of DFO-C4 (pH = 7) were added into the reaction vial. After incubation for 120 min at 37 o C, the reaction progress was monitored by ITLC using a 20 mM citric acid (pH 4.9-5.1) mobile phase. The decay corrected radiochemical yield was consistently > 98.5%.
Iodination with iodine-125 was done in pre-coated iodination tubes (Pierce). 100 µg of C4 was dispersed in 100 µL of PBS solution and added to the pre-coated iodination tubes. In a separate 1.5 mL eppendorf tube, 1 µL of HCl (0.2 M), 2.5 µL of phosphate buffer (0.5 M, pH = 8), 10 µL of potassium iodide solution (1 mg/ml) was prepared. 1 mCi of iodine-125 was added into the eppendorfs and then added to the iodination tubes. After 15 min of reaction the solution was halted and purified via PD10 column using PBS as the mobile phase. The purity was assessed via iTLC, and was consistently >98% pure.
Determination of chelate number: The number of DFO attached to the Ab was measured with a radiometric isotopic dilution assays. From a stock solution, aliquots of 89 Zr-oxalate (10 µL, 20 µCi, pH7.7-7.9) were added to 12 solutions containing 1:2 serial dilutions of nonradioactive ZrCl4(aq.) (100 µL fractions; 1000-0.5 pmol, pH7.7). The mixture was vortexed for 30 s before adding 5 µL aliquots of C4 (5 mg/mL, 2.5 µg of mAb, sterile PBS). The reactions were incubated at room temperature for >2 h before quenching with DTPA (20 µL, 50 mM, pH7.0). Control experiments confirmed that 89 Zr complexation to DFO-conjugated proteins was complete in <2 h. The extent of complexation was assessed by iTLC and counting the activity at the baseline and solvent front. The fraction of 89 Zr-radiolabelled protein (Ab) was plotted versus the amount of non-radioactive ZrCl4 added. The number of chelates was calculated by measuring the concentration of ZrCl4 at which only 50% of the protein was labelled, multiplying by a factor of 2, and then dividing by the moles of protein present in the reaction. Isotopic dilution assays revealed an average of 1.08 ±0.3 accessible chelates per protein molecule for C4.
Immunoreactive fraction: Five different dilutions of cells ranging from 0.5 to 10 million cells/mL were prepared in PBS solution containing BSA. 10 µCi of 89 Zr-C4 was incubated for 1 hour at room temperature in each cellular fraction. Following the incubation, the cell suspensions were washed twice with ice-cold PBS and centrifuged. The radioactivity associated with cell pellet (cell-bound activity) was determined by counting the tubes in a gamma counter with corresponding standards and blanks (for nonspecific binding). The inverse of cell-bound radioactivity (total over bound) was plotted as a function of the inverse of cell concentration. The data was fitted to a linear fit according to a least squares linear regression methods. The Yintercept of the regression line represents the inverse of immunoreactive fraction.
Serum stability determination:
In vitro stability of DFO-mAb was assessed in serum for up to 3 days. For the serum stability studies, 50 µCi 89 Zr-DFO-mAb was added to 500 µL of 100% fetal bovine serum and the mixture was incubated at 37 °C. Aliquots were reserved at different time points: 1h, 4h, 24h, 75h and 5days and assessed by ITLC. Activity within the serum samples was resolved by ITLC and each experiment was carried out in triplicate.
Saturation Binding Assay: The number of PD-L1 receptors per cells was determined by a saturation binding experiment performed in H1975, A549, and PC3 cells using 125 I-C4. The amount of radioligand added was increased while maintaining a constant number of cells/receptors. The three saturation binding assays were done with a range of 9 different concentrations between 0.65 to 120 nM of the radioligand. The non-specific binding was determined at 3 different concentrations (0.65, 10 and 120 nM) by co-incubation of separate treatment arms with a 1000 fold excess over the K D of unlabeled C4. Cells were incubated at 4 o C for 1 hour to achieve equilibrium. Following incubation, the cells were washed twice with ice cold PBS and retained for analysis (unbound fraction). The cells were lysed with 1 mL of 1 M NaOH and collected (bound fraction). The unbound and cell associated fractions were counted in a gamma counter and expressed as a percentage of the total activity added per number of cells. Experiments were performed in triplicate. The specific binding was obtained by subtracting the non-specific binding from total. The specific binding was plotted against the concentration of the radioligand. A Rosenthal plot was used to determine the B max with PRISM software. Cellular uptake assays: Cells were seeded at a density of 4x10 5 cells per well in 12-well plates and grown at 37C, 5% CO2 for 24h. Cells were treated with vehicle or the indicated therapy for 24, 48, or 72 hours. Doxorubucin was used at doses of 100 nM and 1 µM, Paclitaxel was used at 200 nM, 2 µM and 20 µM. On the day of the experiment, cells were subjected to a PBS wash followed by incubation for 1 hour at 37C, 5% CO 2 in PBS with 125 I-C4 (0.5 µCi). Following incubation, the cells were washed twice with ice cold PBS and retained for analysis (externalized fraction). The cells were lysed with 1 mL of 1M NaOH and collected (cell associated fraction). The externalized and cell associated fractions were counted in a gamma counter and expressed as a percentage of the total activity added per equal relative number of cells. Experiments were performed in triplicate. The cell associated activity was expressed as a % of total activity to which the cells were exposed. This value was further normalized to cell number to correct for treatment induced changes in cell viability (determined by treating and counting separate wells containing cells).
Small animal PET/CT: Three to five week old male nu/nu immunocompromised mice and immunocompetent C57BL/6 mice were purchased from Charles River. Nu/Nu mice were inoculated with 1x 10 6 H1975 or A549 cells subcutaneously into one flank in a 1:1 mixture (v/v) of PBS and Matrigel (Corning). Tumors were palpable within 8-14 days with H1975 and 14-21 days with A549 after injection. Three to five week old male C57BL/6 mice (Charles River) were inoculated with 1x 10 6 B16F10 subcutaneously into one flank in the same mixture of matrigel and PBS. Tumors were palpable within 3-5 days after injection. Tumor bearing mice (n=5 per treatment arm) received between 50 to 300 µCi of solution in 100 µL saline solution volume intravenously using a custom mouse tail vein catheter with a 28-gauge needle and a 100-150 mm long polyethylene microtubing. ~300 µCi was injected for the mice for imaging and ~ 50 µCi for the mice for biodistribution. The mice were imaged on a dedicated small animal PET/CT scanner (Inveon, Siemens Healthcare, Malvern, PA). Mice were imaged at multiple time points post injection out to 5 days. Animals were scanned for 20 minutes for PET, and the CT acquisition was 10 minutes.
The co-registration between PET and CT images was obtained using the rigid transformation matrix from the manufacturer-provided scanner calibration procedure since the geometry between PET and CT remained constant for each of PET/CT scans using the combined PET/CT scanner. During the imaging procedure, animals were anesthetized with gas isoflurane at 2% concentration mixed with medical grade oxygen. The photon attenuation correction was performed for PET reconstruction using the co-registered CT-based attenuation map to ensure the quantitative accuracy of the reconstructed PET data.
Biodistribution studies: Biodistribution studies were conducted to evaluate the uptake of 89 Zr-C4 in mice bearing subcutaneous tumors. At a dedicated time after radiotracer injection, animals were euthanized by CO 2 (g) asphyxiation, and 14 tissues (including the tumor) will be removed, weighed and counted on a gamma-counter for accumulation of 89 Zr-radioactivity. The mass of 89 Zr-C4 formulation injected into each animal was measured and used to determine the total number of counts per minute by comparison to a standard syringe of known activity and mass. The data were background-and decay-corrected and the tissue uptake was expressed in units of percentage injected dose per gram of dry tissue (%ID/g).
Animal therapy studies: Tumor bearing mice were injected intraperitoneally with doxorubicin (sigma, 2 mg/kg body weight; equivalent to a dose of 6.5 mg/m 2 in patients). All mice were treated once per day for 6 days (4 days before the injection and 2 days following the radiotracer injection). Taxol was suspended in HPMT solution (0.5% w/v hydroxypropyl-methylcellulose dissolved in water plus 0.2% v/v Tween 80). Tumor bearing mice were treated once daily via oral gavage with Taxol (25 mg/kg/d) for 6 days (4 days before the injection and 2 days following the radiotracer injection).
Statistical Analysis: Data were analyzed using the unpaired, two-tailed Student's t-test. Differences at the 95% confidence level (P < 0.05) were considered to be statistically significant. 
